BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 33108969)

  • 21. Lymph node metastases and elevated postoperative calcitonin: Predictors of poor survival in medullary thyroid carcinoma.
    Siironen P; Hagström J; Mäenpää HO; Louhimo J; Arola J; Haglund C
    Acta Oncol; 2016; 55(3):357-64. PubMed ID: 26339947
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long-Term Follow-up in Medullary Thyroid Carcinoma.
    Raue F; Frank-Raue K
    Recent Results Cancer Res; 2015; 204():207-25. PubMed ID: 26494391
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long-Term Oncologic Outcomes After Curative Resection of Familial Medullary Thyroid Carcinoma.
    Spanheimer PM; Ganly I; Chou J; Capanu M; Ghossein RA; Tuttle RM; Wong RJ; Shaha AR; Untch BR
    Ann Surg Oncol; 2019 Dec; 26(13):4423-4429. PubMed ID: 31549322
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Different outcomes in sporadic versus familial medullary thyroid cancer.
    Saltiki K; Simeakis G; Anagnostou E; Zapanti E; Anastasiou E; Alevizaki M
    Head Neck; 2019 Jan; 41(1):154-161. PubMed ID: 30548085
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Can We Predict the Lateral Compartment Lymph Node Involvement in RET-Negative Patients with Medullary Thyroid Carcinoma?
    Chandeze MM; Noullet S; Faron M; Trésallet C; Godiris-Petit G; Tissier F; Buffet C; Leenhardt L; Chereau N; Menegaux F
    Ann Surg Oncol; 2016 Oct; 23(11):3653-3659. PubMed ID: 27271930
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Exceptionality of Distant Metastasis in Node-Negative Hereditary and Sporadic Medullary Thyroid Cancer: Lessons Learned.
    Machens A; Lorenz K; Weber F; Dralle H
    J Clin Endocrinol Metab; 2021 Jul; 106(8):e2968-e2979. PubMed ID: 33788951
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical utility of genetic diagnosis for sporadic and hereditary medullary thyroid carcinoma.
    Elisei R; Bottici V; Cappagli V; Ramone T; Tacito A; Ciampi R; Romei C
    Ann Endocrinol (Paris); 2019 Jun; 80(3):187-190. PubMed ID: 31053251
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prognostic significance of extranodal extension of regional lymph node metastasis in papillary thyroid cancer.
    Wu MH; Shen WT; Gosnell J; Duh QY
    Head Neck; 2015 Sep; 37(9):1336-43. PubMed ID: 24821456
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Timing and extent of thyroid surgery for gene carriers of hereditary C cell disease--a consensus statement of the European Society of Endocrine Surgeons (ESES).
    Niederle B; Sebag F; Brauckhoff M
    Langenbecks Arch Surg; 2014 Feb; 399(2):185-97. PubMed ID: 24297502
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Rationale for central and bilateral lymph node dissection in sporadic and hereditary medullary thyroid cancer.
    Scollo C; Baudin E; Travagli JP; Caillou B; Bellon N; Leboulleux S; Schlumberger M
    J Clin Endocrinol Metab; 2003 May; 88(5):2070-5. PubMed ID: 12727956
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Surgical management and follow-up of medullary thyroid carcinoma.
    Marzano LA; Porcelli A; Biondi B; Lupoli G; Delrio P; Lombardi G; Zarrilli L
    J Surg Oncol; 1995 Jul; 59(3):162-8. PubMed ID: 7609522
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Current understanding and management of medullary thyroid cancer.
    Roy M; Chen H; Sippel RS
    Oncologist; 2013; 18(10):1093-100. PubMed ID: 24037980
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Identifying risk factors of lateral lymph node recurrence in clinically node-negative papillary thyroid cancer.
    Ryu YJ; Kang SJ; Cho JS; Yoon JH; Park MH
    Medicine (Baltimore); 2018 Dec; 97(51):e13435. PubMed ID: 30572443
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Familial non-multiple endocrine neoplasia medullary thyroid carcinoma: report of a case confirming a new clinical entity in Japan.
    Katagiri M; Ohtawa T; Ito K; Harada T
    Surg Today; 1995; 25(9):822-6. PubMed ID: 8555702
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Surgical approach to the management of medullary thyroid cancer: when is lymph node dissection needed?
    Stamatakos M; Paraskeva P; Katsaronis P; Tasiopoulou G; Kontzoglou K
    Oncology; 2013; 84(6):350-5. PubMed ID: 23689063
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Medullary thyroid carcinoma in Northern Ireland, 1967-1997.
    Dolan SJ; Russell CF
    Ann R Coll Surg Engl; 2000 May; 82(3):156-61. PubMed ID: 10858675
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Grading of medullary thyroid carcinoma on the basis of tumor necrosis and high mitotic rate is an independent predictor of poor outcome.
    Alzumaili B; Xu B; Spanheimer PM; Tuttle RM; Sherman E; Katabi N; Dogan S; Ganly I; Untch BR; Ghossein RA
    Mod Pathol; 2020 Sep; 33(9):1690-1701. PubMed ID: 32313184
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Preoperative basal calcitonin and tumor stage correlate with postoperative calcitonin normalization in patients undergoing initial surgical management of medullary thyroid carcinoma.
    Yip DT; Hassan M; Pazaitou-Panayiotou K; Ruan DT; Gawande AA; Gaz RD; Moore FD; Hodin RA; Stephen AE; Sadow PM; Daniels GH; Randolph GW; Parangi S; Lubitz CC
    Surgery; 2011 Dec; 150(6):1168-77. PubMed ID: 22136837
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Surgery for lymph node metastases of medullary thyroid carcinoma: A review.
    Jin LX; Moley JF
    Cancer; 2016 Feb; 122(3):358-66. PubMed ID: 26539937
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Presurgical assessment of the tumor burden of familial medullary thyroid carcinoma by calcitonin testing.
    Pomares FJ; Rodríguez JM; Nicolás F; Sola J; Canteras M; Balsalobre M; Pascual M; Parrilla P; Tébar FJ
    J Am Coll Surg; 2002 Nov; 195(5):630-4. PubMed ID: 12437249
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.